^
Association details:
| Biomarker: | TMB-L |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
318O - Both low and high blood tumour mutational burden are favourable predictors with atezolizumab
Published date:
11/24/2019
Excerpt:
The median PFS and OS of patients with low and high bTMB were significantly longer than those of patients with medium bTMB in multivariate analysis. Both high and low bTMB were associated with better clinical benefit with atezolizumab.
